Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications last 30 days publications
Nº publicación: EP3044163A1 20/07/2016
ESPCI PARISTECH [FR]
Use of a composition of nanoparticles for gluing at least one hydrogel to at least one other article. Gel assemblies of good mechanical resistance can be obtained easily. Method for gluing at least one hydrogel to at least one other article, said method comprises: applying a composition of nanoparticles on at least one face of the hydrogel and applying the face of the hydrogel with the nanoparticles to the article.
Nº publicación: EP3043781A1 20/07/2016
ARBOR THERAPEUTICS LLC [US]
In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.
Nº publicación: EP3043782A1 20/07/2016
CT DE NEUROCI\u00C9NCIAS E BIOLOG CELULAR [PT]
The present subject matter relates to light-activatable polymeric nanoparticles (NPs) for the transportation and release of an active substance, methods for obtain said particles and their uses. A light-activatable nanoparticle for the transportation and release of an active substance, comprising a polycation preferably a polimer polycation, a polyanion and a light-sensitive photochrome attached to the polycation or the polyanion, wherein said photochrome is hydrophobic and suitable to photo-cleave when activated by an irradiation source, generating a negative charge and releasing the active substance. Light-activatable. The disclosure subject matter shows that NPs are a highly efficient drug delivery system to primary leukemic cells based on opto-nanomedicine system. Therefore, the present disclosure is useful for remote control in the release of biomolecules with spatio-temporal resolution with applications in the areas of general therapeutic and regenerative medicine applications.
Nº publicación: JP2016128404A 14/07/2016
The present invention relates to a liquid lipid core/solid lipid shell capsule surface-functionalized with at least one compound containing at least one amino function, characterized in that the lipid core/lipid shell architecture is on the nanometric scale and in that said compound is covalently bonded to said solid lipid shell via a transacylation reaction. It also relates to a method for preparing such capsules.
Nº publicación: JP2016128522A 14/07/2016
Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles. In the preferred embodiment, the molecular weight of the emulsifiers is less than 1500, 1300, 1200, 1000, 800, 600, or 500 amu. Preferred emulsifiers include cholic acid sodium salt, dioctyl sulfosuccinate sodium, hexadecyltrimethyl ammonium bromide, saponin, TWEEN TM 20, TWEEN TM 80, and sugar esters.; The surface altering materials are present in an amount effective to make the surface charge of the particles neutral or essentially neutral when the one or more emulsifiers are charged. The emulsifiers have an emulsification capacity of at least about 50%, preferably at least 55, 60, 65, 70, 75, 80, 85, 90, or 95%.
Nº publicación: JP2016128571A 14/07/2016
Disclosed is a novel means whereby cyanoacrylate polymer particles that are more useful than conventional product as an antimicrobial agent, antitumor agent, or the like can be provided. This method for manufacturing cyanoacrylate polymer particles includes anionically polymerizing cyanoacrylate monomer in the presence of at least one type of compound selected from the group consisting of an amino acid, a derivative thereof, and an oligomer and polymer thereof, and substantially in the absence of a saccharide or polysorbate. Cyanoacrylate nanoparticles conjugated with amino acid molecules demonstrate cytotoxic activity by specifically adhering to cells, and effectively suppress the proliferation of cancer cells and bacteria. Manufacturing nanoparticles using this novel manufacturing method makes it possible to enhance the cytotoxic activity of the particles.
Nº publicación: JP2016520572A 14/07/2016
The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
Nº publicación: JP2016520518A 14/07/2016
This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including cytotoxic lymphocytes, for use as a powerful tool for immunotherapy.
Nº publicación: JP2016520567A 14/07/2016
Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.
Nº publicación: JP2016520606A 14/07/2016
A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
Nº publicación: WO2016112314A1 14/07/2016
PURDUE RESEARCH FOUNDATION [US]
The invention relates generally to a radio-sensitization method to enhance the effectiveness of radiation therapy for treatment of cancer. Specifically, the invention relates to the use of radio-luminescent particles for sensitizing tumor cells to radiation therapy.
Nº publicación: US2016199309A1 14/07/2016
NANOPHARMACEUTICALS LLC [US]
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.
Nº publicación: US2016199447A1 14/07/2016
PRAXIS BIOPHARMA RES INST [ES]
The present invention refers to lipid nanoparticles comprising a growth factor and / or an antimicrobial lipid and to the method for their preparation. Moreover, it refers to pharmaceutical compositions comprising such lipid nanoparticles, and a pharmaceutically acceptable carrier. Finally, it also refers to said pharmaceutical composition for its use as a medicament and for its use to promote wound healing, particularly by topical administration.
Nº publicación: US2016199516A1 14/07/2016
UNIV TEXAS [US]
The present disclosure relates to a novel type of recognitive biodegradable nanoparticles and their preparations. In particular, the present disclosure relates to combinations of MIPs and biodegradable nanoparticles. One aspect of the present disclosure is directed to a composition comprising: an outer shell having at least one binding cavity specific for a target molecule; and a biodegradable inner core substantially free of the binding cavity.
Nº publicación: WO2016110839A1 14/07/2016
B G NEGEV TECHNOLOGIES AND APPLIC LTD AT BEN GURION UNIVERSITY [IL]
The invention provides a nano-sized particle comprising a cross-linked polymer, wherein the polymer is selected from the group consisting of a polyacrylic acid homopolymer; polymethacrylic acid homopolymer; poly(alkylcyanoacrylate) polymer; a copolymer comprising at least two monomers selected from acrylic acid, methacrylic acid, hydroxyethyl acrylate, hydroxyethyl methacrylate, and alkyl cyanoacrylate/ cyanoacrylic acid monomers; carboxymethyl cellulose; alginic acid polymer, polylactic-polyglycolic acid (PLGA), and xanthan gum; and wherein said polymer is cross-linked with a metal ion. A process for preparing such particles is also provided.
Nº publicación: WO2016110228A1 14/07/2016
BRIGHTGENE BIO MEDICAL TECHNOLOGY CO LTD [CN]
The invention discloses a hyaluronic-acid-based amphiphilic polymer as well as a preparation method and an application thereof. The main chain of the amphiphilic polymer is hydrophilic hyaluronic acid and has an active targeting capacity; the side chain of the synergistic effect is hydrophobic lysine methyl ester-lipoyl; the amphiphilic polymer can load a micromolecular anti-cancer drug and nano particles of the polymer is obtained by virtue of chemical crosslinking, so that the nano particles are hardly dissociated out of cells and in blood, thereby guaranteeing the stability of the drug encapsulated by the nano particles; once the drug reaches the tumor tissues, hyaluronic acid on the surface of the nano particles can be tightly combined with a CD44 acceptor on the surface of the tumor cell and effectively enter into the tumor cell by virtue of endocytosis mediated by the acceptor and are quickly decrosslinked to be dissociated, so that the drug is quickly released and the enrichment ratio of the drug in the tumor part is high and reaches 12.71% ID/g which is far higher than the level in the prior art, thereby generating an efficient treatment effect; the defects that the drug in vivo is easy to leak, low in transfer efficiency, less in endocytosis, slow in release in cells and the like.
Nº publicación: US2016199502A1 14/07/2016
UNIV RUTGERS [US]
US ARMY SECRETARY OF THE ARMY [US]
Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes.
Nº publicación: US2016199497A1 14/07/2016
PURDUE RESEARCH FOUNDATION [US]
The present invention provides a formulation for reducing the hydrophobicity of ACAT-1 inhibitors. Methods for using the formulation of the present invention are also provided.
Nº publicación: BR102014031064A2 12/07/2016
UNIV ESTADUAL DE PONTA GROSSA [BR]
UNIV FED DO PARAN\u00C1 [BR]
processo de produção de anticoagulante através da conjugação de heparina com poli(ácido lático) e sua nanoencapsulação. a presente invenção refere-se à produção de um anticoagulante através da conjugação da molécula de heparina com a molécula do poli(ácido lático) de baixa massa molar e posterior nanoencapsulação, permitindo, assim, sua administração oral e ação anticoagulante prolongada pela absorção gastrointestinal, para pacientes com trombose venosa profunda.
Nº publicación: JP2016520124A 11/07/2016
The present invention relates to a composition for mucus dispersion or hydration, containing a poly-[gamma]-glutamic acid, which is a biocompatible natural polymer, and more specifically, to a composition for treating mucus hypersecretion disease, containing a poly-[gamma]-glutamic acid or a poly-[gamma]-glutamic acid nanogel. The present invention is useful for treating diseases associated with mucus through the effective dispersion and hydration of mucus, which is hypersecreted in vivo and has a high viscosity.
Nº publicación: JP2016520141A 11/07/2016
Novel pentablock polymers having a PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG- PGA-PCL configuration, wherein PEG is polyethylene glycol, PCL is poly(8-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid), and methods of making nanoparticles from the pentablock polymers, are disclosed. The invention is also directed to a method for preparing nanoparticle compositions comprised of polymers with high levels of bioactive or diagnostic agents.
Nº publicación: JP2016520051A 11/07/2016
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
Nº publicación: RU2014150850A 10/07/2016
The disclosure relates to nanoparticles comprising poly(octylcyanoacrylate) for oral administration of a biologically active polypeptide, in particular a metabolic peptide, such as exendin-4. Also disclosed are methods of producing such nanoparticles, pharmaceutical compositions comprising such nanoparticles and methods of treating metabolic disorders, such as obesity, using such nanoparticles.
Nº publicación: RU2014151603A 10/07/2016
LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided.
Nº publicación: HK1213444A1 08/07/2016
MAYO FOUND FOR MEDICAL EDUCATION AND RES [US]
This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE TM /anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.